Genmab Shares Plunge 6.55% Amid Buyback, Trial Results

Genmab(GMAB) shares fell 1.15% today, marking the third consecutive day of decline, with a total drop of 6.55% over the past three days. The share price hit its lowest level since March 2020, with an intraday decline of 2.31%.

Genmab's recent stock price fluctuations can be attributed to several key factors. On March 25, 2025, the company announced the initiation of a share buy-back program, aiming to repurchase up to 2.2 million shares. This strategic move is designed to reduce the company's capital, potentially increasing earnings per share and signaling confidence in its financial health. Such programs often have a positive impact on stock prices as they can enhance investor sentiment and demonstrate the company's commitment to shareholder value.

Additionally, Genmab, in collaboration with Seagen Inc., reported positive results from the Phase 3 innovaTV 301 global trial. Successful trial outcomes are crucial for pharmaceutical companies as they pave the way for regulatory approval and potential revenue generation from new treatments. Positive trial results can significantly boost stock prices by enhancing the company's prospects and investor confidence in its future growth and profitability.